Analytical performance of a standardized single‐platform MHC tetramer assay for the identification and enumeration of CMV‐specific CD8+ T lymphocytes

Major histocompatibility complex (MHC) multimers that identify antigen‐specific T cells, coupled with flow cytometry, have made a major impact on immunological research. HLA Class I multimers detect T cells directed against viral, tumor, and transplantation antigens with exquisite sensitivity. This technique has become an important standard for the quantification of a T cell immune response. The utility of this method in multicenter studies, however, is dependant on reproducibility between laboratories. As part of a clinical study using a standardized two‐tube three‐color single‐platform method, we monitored and characterized performance across multiple sites using tetramers against the T cell receptors (TCR) specific for MHC Class I, A*0101—VTEHDTLLY, A*0201—NLVPMVATV and B*0702—TPRVTGGGAM CMV peptides. We studied the analytical performance of this method, focusing on reducing background, maximizing signal intensity, and ensuring that sufficient cells are enumerated to provide meaningful statistics. Inter and intra‐assay performance were assessed, which included inherent variability introduced by shipping, type of flow cytometer used, protocol adherence, and analytical interpretation across a range of multiple sample levels and specificities under routine laboratory testing conditions. Using the described protocol, it is possible to obtain intra‐ and interlab CV's of <20%, with a functional sensitivity for absolute tetramer counts of 1 cell/μL and 0.2% tetramer+ percent for A*0101, A*0201, and B*0702 alleles. The standardized single‐platform MHC tetramer assay is simple, rapid, reproducible, and useful for assessing CMV‐specific T cells, and will allow for reasonable comparisons of clinical evaluations across multiple centers at clinically relevant thresholds (2.0–10.0 cells/μL). © 2008 International Society for Advancement of Cytometry

[1]  P. Dellabona,et al.  Use of MHC class II tetramers to investigate CD4+ T cell responses: Problems and solutions , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[2]  B. van der Holt,et al.  Monitoring cytomegalovirus IE‐1 and pp65‐specific CD4+ and CD8+ T‐cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations , 2008, Cytometry. Part B, Clinical cytometry.

[3]  F. Brun-Vézinet,et al.  Proliferative, IFNγ and IL-2-producing T-cell responses to HIV-2 in untreated HIV-2 infection , 2006, AIDS.

[4]  M. Roederer,et al.  Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. , 2005, Trends in immunology.

[5]  T. Schumacher,et al.  MHC multimer technology: current status and future prospects. , 2005, Current opinion in immunology.

[6]  C. Nugent,et al.  Low binding capacity of murine tetramers mutated at residue 227 does not preclude the ability to efficiently activate CD8+ T lymphocytes. , 2005, Immunology letters.

[7]  L. K. Ely,et al.  The CDR3 regions of an immunodominant T cell receptor dictate the 'energetic landscape' of peptide-MHC recognition , 2005, Nature Immunology.

[8]  F. Kern,et al.  Enumeration of antigen‐specific CD8+ T lymphocytes by single‐platform, HLA tetramer‐based flow cytometry: A European multicenter evaluation , 2004, Cytometry. Part B, Clinical cytometry.

[9]  F. Miedema,et al.  Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. , 2003, Blood.

[10]  O. Korsgren,et al.  Cellular responses to cytomegalovirus in immunosuppressed patients: circulating CD8+ T cells recognizing CMVpp65 are present but display functional impairment , 2003, Clinical and experimental immunology.

[11]  E. Remmerswaal,et al.  Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. , 2003, Blood.

[12]  S. Rowland-Jones,et al.  Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. , 2002, Blood.

[13]  W. Leisenring,et al.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. , 2002, Blood.

[14]  Mark M. Davis,et al.  Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients1 , 2002, Transplantation.

[15]  L. Picker,et al.  Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. , 2002, The Journal of infectious diseases.

[16]  D. Busch,et al.  Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer , 2002, Nature Medicine.

[17]  J. Gratama,et al.  Reduction of variation in T-cell subset enumeration among 55 laboratories using single-platform, three or four-color flow cytometry based on CD45 and SSC-based gating of lymphocytes. , 2002, Cytometry.

[18]  P. Klenerman,et al.  Tracking T cells with tetramers: new tales from new tools , 2002, Nature Reviews Immunology.

[19]  S. Grace,et al.  Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. , 2001, The Journal of infectious diseases.

[20]  C. Tournay,et al.  Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. , 2001, Blood.

[21]  A. Meyerhans,et al.  LEVELS OF VIRUS-SPECIFIC CD4 T CELLS CORRELATE WITH CYTOMEGALOVIRUS CONTROL AND PREDICT VIRUS-INDUCED DISEASE AFTER RENAL TRANSPLANTATION1 , 2001, Transplantation.

[22]  C. Craddock,et al.  Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. , 2001, Blood.

[23]  D. Pillay,et al.  Direct visualization and quantitation of cytomegalovirus-specific CD8+ cytotoxic T-lymphocytes in liver transplant patients. , 2000, Transplantation.

[24]  S. Papa,et al.  Reduction of intra‐ and interlaboratory variation in CD34+ stem cell enumeration using stable test material, standard protocols and targeted training , 2000, British journal of haematology.

[25]  P. Griffiths,et al.  Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. , 1999, The Journal of infectious diseases.

[26]  P. Moss,et al.  Tetrameric HLA class I–minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease , 1999, Nature Medicine.

[27]  F. Lacroix,et al.  Impact of unified procedures as implemented in the Canadian Quality Assurance Program for T lymphocyte subset enumeration. Participating Flow Cytometry Laboratories of the Canadian Clinical Trials Network for HIV/AIDS Therapies. , 1998, Cytometry.

[28]  E. Jaffee,et al.  Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Ogg,et al.  Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo , 1998, The Journal of experimental medicine.

[30]  J. Altman,et al.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.

[31]  X. Jin,et al.  The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL , 1996, Journal of virology.

[32]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[33]  P. Doherty,et al.  Establishment and Persistence of Virus‐Specific CD4+ and CD8+ T Cell Memory , 1996, Immunological reviews.

[34]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[35]  S. Riddell,et al.  Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. , 1994, Blood.

[36]  G. Gahrton,et al.  Cytomegalovirus viraemia and specific T‐helper cell responses as predictors of disease after allogeneic marrow transplantation , 1993, British journal of haematology.

[37]  M. Boeckh,et al.  Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. , 1992, Blood.

[38]  S. Riddell,et al.  Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.

[39]  William J. Britt,et al.  Primary cytomegalovirus infection in pregnancy: comparison of antibody responses to virus-encoded proteins between women with and without intrauterine infection. , 1988, The Journal of infectious diseases.

[40]  B. Bloom In vitro methods in cell-mediated immunity in man. , 1971, The New England journal of medicine.

[41]  J. Altman Flow cytometry applications of MHC tetramers. , 2004, Methods in cell biology.

[42]  J. Gratama,et al.  Diagnostic potential of tetramer-based monitoring of cytomegalovirus-specific CD8+ T lymphocytes in allogeneic stem cell transplantation. , 2003, Clinical immunology.

[43]  J. Gratama,et al.  Validation of the single-platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. , 2003, Cytotherapy.

[44]  D. Pillay,et al.  Characterization of CMVpp65-Specific CD81 T Lymphocytes Using MHC Tetramers in Kidney Transplant Patients and Healthy Participants. Transplantation 2000; 69: 2243. , 2000 .

[45]  E. Reinherz,et al.  The human T-cell receptor. , 1984, Annual review of immunology.

[46]  Ozdemir,et al.  Differentiation of Cytomegalovirus-specific Cd8 , 2022 .